675 Arapeen Drive
Salt Lake City,
United States - Map
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing, is in Phase III clinical study. The companys pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase II clinical study; and LPCN 1107, which is in Phase I clinical study for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
|Dr. Mahesh V. Patel Ph.d.,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Mr. Morgan R. Brown CPA, MBA,
Chief Financial Officer, Exec. VP and Corp. Sec.
|Dr. William I. Higuchi Ph.D.,
Chief Scientific Consultant
|Dr. Jyrki Mattila M.D., Ph.D., MBA,
Chief Bus. Officer and Exec. VP
|Dr. Anthony DelConte M. D.,
Chief Medical Director
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|